Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

EDWIN C KINGSLEY

Allopathic & Osteopathic Physicians Internal Medicine Hematology & Oncology

NPI
1336156199
CMS profile
429695
Location
LAS VEGAS, NV

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2024 · Entire year

$1,764.50

107 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2024 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $1,670.66 105
Education $93.84 2

By paying entity

PY2024 · entire year · sorted by reported total

Page 3 of 3; records 101–107 of 107 matching records. This page contains 7 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

EDWIN C KINGSLEY

NPI 1336156199 · CMS profile ID 429695

Allopathic & Osteopathic Physicians / Internal Medicine / Hematology & Oncology

LAS VEGAS, NV

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 3 of 3; records 101–107 of 107 matching records. This page contains 7 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1336156199?year=2024&recipient=provider&page=3#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
EDWIN C KINGSLEY, NPI 1336156199, CMS profile ID 429695. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 3; records 101–107 of 107 matching records. This page contains 7 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1336156199?year=2024&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
APA 7
IndustryPayments. (2026). EDWIN C KINGSLEY, NPI 1336156199, CMS profile ID 429695. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 3; records 101–107 of 107 matching records. This page contains 7 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1336156199?year=2024&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
Bluebook
EDWIN C KINGSLEY, NPI 1336156199, CMS profile ID 429695, IndustryPayments, General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 3 of 3; records 101–107 of 107 matching records. This page contains 7 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff. https://industrypayments.org/provider/npi-1336156199?year=2024&recipient=provider&page=3#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2024

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2024 · Physicians and non-physician practitioners · CMS publication 2026-06-30

107 matching records · $1,764.50 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 107 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 101–107 of 107.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Daiichi Sankyo Inc. $11.2001/25/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1089442955 CMS
Lilly USA, LLC $75.7501/20/2024 Education No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1136149808 CMS
Daiichi Sankyo Inc. $4.0001/18/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1089442947 CMS
Celgene Corporation $16.3301/11/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1101180450 CMS
Daiichi Sankyo Inc. $12.9401/11/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1089442949 CMS
GENZYME CORPORATION $20.6901/09/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1139769594 CMS
Daiichi Sankyo Inc. $7.1401/05/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1089442951 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $120.09 2
PY2021 $166.87 1
PY2022 $315.46 17
PY2023 $1,827.76 90
PY2024 $1,764.50 107
PY2025 $1,610.64 95

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Source files
Dataset page · Bulk file · PY2019 , PY2021 , PY2022 , PY2023 , PY2024 , PY2025
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Recipient $4,470.00 3
PY2025 Principal investigator $1,081,010.47 106
PY2024 Principal investigator $1,200,370.40 143
PY2023 Principal investigator $1,807,505.27 137
PY2022 Principal investigator $1,345,279.52 113
PY2021 Principal investigator $2,354,079.39 172
PY2020 Principal investigator $1,249,873.38 196
PY2019 Recipient $1,063.00 1
PY2019 Principal investigator $138,554.96 134

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

109 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Merck Sharp & Dohme LLC $27,342.02 12/31/2025 Non-covered Recipient Entity
Comprehensive Cancer Centers of Nevada
A Phase 2 Study to Evaluate the Pharmacokinetics, Efficacy, and Safety of Subcutaneous Pembrolizumab Coformulated With Hyaluronidase MK-3475A in Participants with Relapsed or Refractory Classical Hodgkin Lymphoma rrcHL or Relapsed or Refractory Primar No dispute reported 06/30/2026 1232928518
Principal investigator 1 BeOne Medicines USA, Inc. $1,825.00 12/30/2025 Non-covered Recipient Entity
Comprehensive Cancer Centers of Nevada - Central Valley
A Phase 2, Multicenter, Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib No dispute reported 06/30/2026 1190327525
Principal investigator 1 BeOne Medicines USA, Inc. $408.00 12/30/2025 Non-covered Recipient Entity
Comprehensive Cancer Centers of Nevada - Central Valley
A Phase 2, Multicenter, Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib No dispute reported 06/30/2026 1190327527
Principal investigator 1 BeOne Medicines USA, Inc. $8,936.00 12/30/2025 Non-covered Recipient Entity
Comprehensive Cancer Centers of Nevada - Central Valley
A Phase 2, Multicenter, Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib No dispute reported 06/30/2026 1190327529
Principal investigator 1 BeOne Medicines Ltd. $4,356.00 12/23/2025 Non-covered Recipient Entity
Comprehensive Cancer Centers of Nevada - Central Valley
A Phase 1/2, Open-Label, Dose-Escalation and -Expansion Study of the Bruton Tyrosine Kinase Targeted Protein Degrader BGB-16673 in Patients With B-Cell Malignancies No dispute reported 06/30/2026 1190333054
Principal investigator 1 BeOne Medicines Ltd. $2,385.00 12/09/2025 Non-covered Recipient Entity
Comprehensive Cancer Centers of Nevada - Central Valley
A Phase 1/2, Open-Label, Dose-Escalation and -Expansion Study of the Bruton Tyrosine Kinase Targeted Protein Degrader BGB-16673 in Patients With B-Cell Malignancies No dispute reported 06/30/2026 1190329157
Principal investigator 1 PFIZER INC. $23,590.88 12/01/2025 Non-covered Recipient Entity
Compr CA Centers of Nev
A PHASE 1 STUDY OF SGNB6A IN ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1228719205
Principal investigator 1 BeOne Medicines USA, Inc. $1,445.00 11/28/2025 Non-covered Recipient Entity
Comprehensive Cancer Centers of Nevada - Central Valley
A Phase 4, Observational Study Evaluating the Efficacy and Safety of the Bruton Tyrosine Kinase (BTK) Inhibitor Zanubrutinib in Patients With Waldenström Macroglobulinemia No dispute reported 06/30/2026 1190329061
Principal investigator 1 PFIZER INC. $23,590.88 11/25/2025 Non-covered Recipient Entity
Compr CA Centers of Nev
A PHASE 1 STUDY OF SGNB6A IN ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1228719199
Principal investigator 1 BeOne Medicines Ltd. $905.00 11/18/2025 Non-covered Recipient Entity
Comprehensive Cancer Centers of Nevada - Central Valley
A Phase 1/2, Open-Label, Dose-Escalation and -Expansion Study of the Bruton Tyrosine Kinase Targeted Protein Degrader BGB-16673 in Patients With B-Cell Malignancies No dispute reported 06/30/2026 1190333058
Principal investigator 1 BeOne Medicines Ltd. $657.00 11/07/2025 Non-covered Recipient Entity
Comprehensive Cancer Centers of Nevada - Central Valley
A Phase 3 Randomized, Open-Label, Multicenter Study Comparing Zanubrutinib (BGB-3111) Plus Rituximab Versus Bendamustine Plus Rituximab in Patients With Previously Untreated Mantle Cell Lymphoma Who Are Ineligible for Stem Cell Transplantation No dispute reported 06/30/2026 1190329269
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $754.26 10/29/2025 Non-covered Recipient Entity
ALLISON CURTIS KINGSLEY MEOZ MICHAEL & SANCHEZ PROF CORP
A RANDOMIZED, OPEN-LABEL, PHASE 3 TRIAL OF A+AVD VERSUS ABVD AS FRONTLINE THERAPY IN PATIENTS WITH ADVANCED CLASSICAL HODGKIN LYMPHOMA No dispute reported 06/30/2026 1223287721
Principal investigator 1 BeOne Medicines USA, Inc. $1,125.00 10/28/2025 Non-covered Recipient Entity
Comprehensive Cancer Centers of Nevada - Central Valley
A Phase 2, Multicenter, Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib No dispute reported 06/30/2026 1190327531
Principal investigator 1 BeOne Medicines USA, Inc. $796.00 10/28/2025 Non-covered Recipient Entity
Comprehensive Cancer Centers of Nevada - Central Valley
A Phase 4, Observational Study Evaluating the Efficacy and Safety of the Bruton Tyrosine Kinase (BTK) Inhibitor Zanubrutinib in Patients With Waldenström Macroglobulinemia No dispute reported 06/30/2026 1190329059
Principal investigator 1 BeOne Medicines Ltd. $1,290.00 10/27/2025 Non-covered Recipient Entity
Comprehensive Cancer Centers of Nevada - Central Valley
An Open-label, Multi-center, Long-term Extension Study of Zanubrutinib (BGB-3111) Regimens in Patients with B-cell Malignancies No dispute reported 06/30/2026 1190334783
Principal investigator 1 BeOne Medicines Ltd. $52,400.00 10/22/2025 Non-covered Recipient Entity
Comprehensive Cancer Centers of Nevada - Central Valley
An Open-label, Multi-center, Long-term Extension Study of Zanubrutinib (BGB-3111) Regimens in Patients With B-cell Malignancies No dispute reported 06/30/2026 1190344122
Principal investigator 1 BeOne Medicines Ltd. $3,820.50 10/21/2025 Non-covered Recipient Entity
Comprehensive Cancer Centers of Nevada - Central Valley
An International, Phase 3, Open-Label, Randomized Study of BGB-3111 Compared With Bendamustine Plus Rituximab in Patients With Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (CLL/SLL) No dispute reported 06/30/2026 1190329803
Principal investigator 1 PFIZER INC. $47,181.76 10/20/2025 Non-covered Recipient Entity
Compr CA Centers of Nev
A PHASE 1 STUDY OF SGNB6A IN ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1228719002
Principal investigator 1 PFIZER INC. $800.00 09/29/2025 Non-covered Recipient Entity
ALLISON CURTIS KINGSLEY ET AL
A PHASE 1 STUDY OF SGNB6A IN ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1228750915
Principal investigator 1 PFIZER INC. $5,619.25 09/29/2025 Non-covered Recipient Entity
ALLISON CURTIS KINGSLEY ET AL
A PHASE 1 STUDY OF SGNB6A IN ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1228758505
Principal investigator 1 PFIZER INC. $6,919.25 09/29/2025 Non-covered Recipient Entity
ALLISON CURTIS KINGSLEY ET AL
A PHASE 1 STUDY OF SGNB6A IN ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1228761114
Principal investigator 1 BeOne Medicines Ltd. $1,962.00 09/23/2025 Non-covered Recipient Entity
Comprehensive Cancer Centers of Nevada - Central Valley
A Phase 1/2, Open-Label, Dose-Escalation and -Expansion Study of the Bruton Tyrosine Kinase Targeted Protein Degrader BGB-16673 in Patients With B-Cell Malignancies No dispute reported 06/30/2026 1190329149
Principal investigator 1 PFIZER INC. $47,181.76 09/23/2025 Non-covered Recipient Entity
Compr CA Centers of Nev
A PHASE 1 STUDY OF SGNB6A IN ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1228719004
Principal investigator 1 PFIZER INC. $62,766.94 09/22/2025 Non-covered Recipient Entity
ALLISON CURTIS KINGSLEY ET AL
A PHASE 1 STUDY OF SGNB6A IN ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1228758304
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,567.00 09/12/2025 Non-covered Recipient Entity
ALLISON CURTIS KINGSLEY MEOZ MICHAEL & SANCHEZ PROF CORP
A RANDOMIZED, OPEN-LABEL, PHASE 3 TRIAL OF A+AVD VERSUS ABVD AS FRONTLINE THERAPY IN PATIENTS WITH ADVANCED CLASSICAL HODGKIN LYMPHOMA No dispute reported 06/30/2026 1223285333
Principal investigator 1 BeOne Medicines Ltd. $4,356.00 09/09/2025 Non-covered Recipient Entity
Comprehensive Cancer Centers of Nevada - Central Valley
A Phase 1/2, Open-Label, Dose-Escalation and -Expansion Study of the Bruton Tyrosine Kinase Targeted Protein Degrader BGB-16673 in Patients With B-Cell Malignancies No dispute reported 06/30/2026 1190333046
Principal investigator 1 BeOne Medicines USA, Inc. $3,375.00 09/09/2025 Non-covered Recipient Entity
Comprehensive Cancer Centers of Nevada - Central Valley
A Phase 2, Multicenter, Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib No dispute reported 06/30/2026 1190327521
Principal investigator 1 BeOne Medicines USA, Inc. $200.00 09/09/2025 Non-covered Recipient Entity
Comprehensive Cancer Centers of Nevada - Central Valley
A Phase 2, Multicenter, Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib No dispute reported 06/30/2026 1190327523
Principal investigator 1 BeOne Medicines Ltd. $1,667.00 09/02/2025 Non-covered Recipient Entity
Comprehensive Cancer Centers of Nevada - Central Valley
A Phase 1/2, Open-Label, Dose-Escalation and -Expansion Study of the Bruton Tyrosine Kinase Targeted Protein Degrader BGB-16673 in Patients With B-Cell Malignancies No dispute reported 06/30/2026 1190329155
Principal investigator 1 Merck Sharp & Dohme LLC $29,943.60 08/31/2025 Non-covered Recipient Entity
Comprehensive Cancer Centers of Nevada
A Phase 2 Study to Evaluate the Pharmacokinetics, Efficacy, and Safety of Subcutaneous Pembrolizumab Coformulated With Hyaluronidase MK-3475A in Participants with Relapsed or Refractory Classical Hodgkin Lymphoma rrcHL or Relapsed or Refractory Primar No dispute reported 06/30/2026 1232928680
Principal investigator 1 PFIZER INC. $23,590.88 08/27/2025 Non-covered Recipient Entity
Compr CA Centers of Nev
A PHASE 1 STUDY OF SGNB6A IN ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1228719203
Recipient PFIZER INC. $3,200.00 08/21/2025 Covered Recipient Physician SIGVOTATUG VEDOTIN CLINICAL PUBLICATION PROGRAM No dispute reported 06/30/2026 1228726560
Principal investigator 1 PFIZER INC. $23,590.88 08/19/2025 Non-covered Recipient Entity
Compr CA Centers of Nev
A PHASE 1 STUDY OF SGNB6A IN ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1228719201
Principal investigator 1 PFIZER INC. $19,500.00 08/18/2025 Non-covered Recipient Entity
ALLISON CURTIS KINGSLEY ET AL
A PHASE 1 STUDY OF SGNB6A IN ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1228789553
Principal investigator 1 PFIZER INC. $23,590.88 08/11/2025 Non-covered Recipient Entity
Compr CA Centers of Nev
A PHASE 1 STUDY OF SGNB6A IN ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1228718999
Principal investigator 1 BeOne Medicines Ltd. $104,800.00 08/05/2025 Non-covered Recipient Entity
Comprehensive Cancer Centers of Nevada - Central Valley
An Open-label, Multi-center, Long-term Extension Study of Zanubrutinib (BGB-3111) Regimens in Patients With B-cell Malignancies No dispute reported 06/30/2026 1190330211
Principal investigator 1 BeOne Medicines Ltd. $1,667.00 07/29/2025 Non-covered Recipient Entity
Comprehensive Cancer Centers of Nevada - Central Valley
A Phase 1/2, Open-Label, Dose-Escalation and -Expansion Study of the Bruton Tyrosine Kinase Targeted Protein Degrader BGB-16673 in Patients With B-Cell Malignancies No dispute reported 06/30/2026 1190329151
Principal investigator 1 BeOne Medicines Ltd. $2,000.00 07/29/2025 Non-covered Recipient Entity
Comprehensive Cancer Centers of Nevada - Central Valley
A Phase 1/2, Open-Label, Dose-Escalation and -Expansion Study of the Bruton Tyrosine Kinase Targeted Protein Degrader BGB-16673 in Patients With B-Cell Malignancies No dispute reported 06/30/2026 1190333050
Principal investigator 1 BeOne Medicines Ltd. $432.00 07/22/2025 Non-covered Recipient Entity
Comprehensive Cancer Centers of Nevada - Central Valley
An International, Phase 3, Open-Label, Randomized Study of BGB-3111 Compared With Bendamustine Plus Rituximab in Patients With Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (CLL/SLL) No dispute reported 06/30/2026 1190332285
Principal investigator 1 BeOne Medicines USA, Inc. $796.00 07/22/2025 Non-covered Recipient Entity
Comprehensive Cancer Centers of Nevada - Central Valley
A Phase 4, Observational Study Evaluating the Efficacy and Safety of the Bruton Tyrosine Kinase (BTK) Inhibitor Zanubrutinib in Patients With Waldenström Macroglobulinemia No dispute reported 06/30/2026 1190329057
Principal investigator 1 PFIZER INC. $23,590.88 07/21/2025 Non-covered Recipient Entity
Compr CA Centers of Nev
A PHASE 1 STUDY OF SGNB6A IN ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1228719117
Principal investigator 1 BeOne Medicines Ltd. $1,290.00 07/18/2025 Non-covered Recipient Entity
Comprehensive Cancer Centers of Nevada - Central Valley
An Open-label, Multi-center, Long-term Extension Study of Zanubrutinib (BGB-3111) Regimens in Patients With B-cell Malignancies No dispute reported 06/30/2026 1190327315
Principal investigator 1 BeOne Medicines Ltd. $500.00 07/09/2025 Non-covered Recipient Entity
Comprehensive Cancer Centers of Nevada - Central Valley
An Open-label, Multi-center, Long-term Extension Study of Zanubrutinib (BGB-3111) Regimens in Patients With B-cell Malignancies No dispute reported 06/30/2026 1190327075
Principal investigator 1 BeOne Medicines Ltd. $350.00 07/09/2025 Non-covered Recipient Entity
Comprehensive Cancer Centers of Nevada - Central Valley
A Phase 3 Randomized, Open-Label, Multicenter Study Comparing Zanubrutinib (BGB-3111) Plus Rituximab Versus Bendamustine Plus Rituximab in Patients With Previously Untreated Mantle Cell Lymphoma Who Are Ineligible for Stem Cell Transplantation No dispute reported 06/30/2026 1190327235
Principal investigator 1 BeOne Medicines Ltd. $1,962.00 07/07/2025 Non-covered Recipient Entity
Comprehensive Cancer Centers of Nevada - Central Valley
A Phase 1/2, Open-Label, Dose-Escalation and -Expansion Study of the Bruton Tyrosine Kinase Targeted Protein Degrader BGB-16673 in Patients With B-Cell Malignancies No dispute reported 06/30/2026 1190329153
Principal investigator 1 Merck Sharp & Dohme LLC $11,000.00 07/01/2025 Non-covered Recipient Entity
Comprehensive Cancer Centers of Nevada
A Phase 2 Study to Evaluate the Pharmacokinetics, Efficacy, and Safety of Subcutaneous Pembrolizumab Coformulated With Hyaluronidase MK-3475A in Participants with Relapsed or Refractory Classical Hodgkin Lymphoma rrcHL or Relapsed or Refractory Primar No dispute reported 06/30/2026 1232928473
Principal investigator 1 BeOne Medicines Ltd. $62,880.00 06/26/2025 Non-covered Recipient Entity
Comprehensive Cancer Centers of Nevada - Central Valley
A Phase 2, Multicenter, Single-arm Study of Zanubrutinib (BGB-3111) in Patients With Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment With Ibrutinib and/or Acalabrutinib No dispute reported 06/30/2026 1190330123
Principal investigator 1 BeOne Medicines Ltd. $4,356.00 06/24/2025 Non-covered Recipient Entity
Comprehensive Cancer Centers of Nevada - Central Valley
A Phase 1/2, Open-Label, Dose-Escalation and -Expansion Study of the Bruton Tyrosine Kinase Targeted Protein Degrader BGB-16673 in Patients With B-Cell Malignancies No dispute reported 06/30/2026 1190333065
Principal investigator 1 PFIZER INC. $464.80 06/20/2025 Non-covered Recipient Entity
Compr CA Centers of Nev
A PHASE 1 STUDY OF SGNB6A IN ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1228759511
Principal investigator 1 PFIZER INC. $464.80 06/19/2025 Non-covered Recipient Entity
Compr CA Centers of Nev
A PHASE 1 STUDY OF SGNB6A IN ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1228756445
Principal investigator 1 BeOne Medicines USA, Inc. $1,445.00 06/17/2025 Non-covered Recipient Entity
Comprehensive Cancer Centers of Nevada - Central Valley
A Phase 4, Observational Study Evaluating the Efficacy and Safety of the Bruton Tyrosine Kinase (BTK) Inhibitor Zanubrutinib in Patients With Waldenström Macroglobulinemia No dispute reported 06/30/2026 1190330917
Principal investigator 1 BeOne Medicines Ltd. $149.50 06/16/2025 Non-covered Recipient Entity
Comprehensive Cancer Centers of Nevada - Central Valley
An International, Phase 2, Open-Label, Randomized Study of BGB-3111 Combined With Obinutuzumab Compared With Obinutuzumab Monotherapy in Relapsed/ Refractory Follicular Lymphoma No dispute reported 06/30/2026 1190326320
Principal investigator 1 PFIZER INC. $12,566.86 06/16/2025 Non-covered Recipient Entity
ALLISON CURTIS KINGSLEY ET AL
A PHASE 1 STUDY OF SGNB6A IN ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1228775415
Principal investigator 1 BeOne Medicines Ltd. $1,345.50 06/11/2025 Non-covered Recipient Entity
Comprehensive Cancer Centers of Nevada - Central Valley
An International, Phase 2, Open-Label, Randomized Study of BGB-3111 Combined With Obinutuzumab Compared With Obinutuzumab Monotherapy in Relapsed/ Refractory Follicular Lymphoma No dispute reported 06/30/2026 1190326318
Principal investigator 1 BeOne Medicines Ltd. $2,802.60 06/10/2025 Non-covered Recipient Entity
Comprehensive Cancer Centers of Nevada - Central Valley
An International, Phase 3, Open-Label, Randomized Study of BGB-3111 Compared With Bendamustine Plus Rituximab in Patients With Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (CLL/SLL) No dispute reported 06/30/2026 1190331185
Principal investigator 1 PFIZER INC. $6,500.00 06/09/2025 Non-covered Recipient Entity
ALLISON CURTIS KINGSLEY ET AL
A PHASE 1 STUDY OF SGNB6A IN ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1228776689
Principal investigator 1 Sumitomo Pharma America, Inc. $3,250.00 06/05/2025 Non-covered Recipient Entity
COMPREHENSIVE CANCER CENTERS OF NEVEDA
A PHASE I, FIRST-IN-HUMAN, OPEN-LABEL, DOSE ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP 1454 No dispute reported 06/30/2026 1176635977
Principal investigator 1 BeOne Medicines Ltd. $1,125.00 06/02/2025 Non-covered Recipient Entity
Comprehensive Cancer Centers of Nevada - Central Valley
A Phase 2, Multicenter, Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib No dispute reported 06/30/2026 1190331445
Recipient PFIZER INC. $940.00 06/02/2025 Covered Recipient Physician SIGVOTATUG VEDOTIN CLINICAL PUBLICATION PROGRAM No dispute reported 06/30/2026 1228769363
Principal investigator 1 BeOne Medicines Ltd. $5,301.00 05/30/2025 Non-covered Recipient Entity
Comprehensive Cancer Centers of Nevada - Central Valley
A Phase 1/2, Open-Label, Dose-Escalation and -Expansion Study of the Bruton Tyrosine Kinase Targeted Protein Degrader BGB-16673 in Patients With B-Cell Malignancies No dispute reported 06/30/2026 1190330911
Principal investigator 1 BeOne Medicines Ltd. $7,706.00 05/30/2025 Non-covered Recipient Entity
Comprehensive Cancer Centers of Nevada - Central Valley
A Phase 1/2, Open-Label, Dose-Escalation and -Expansion Study of the Bruton Tyrosine Kinase Targeted Protein Degrader BGB-16673 in Patients With B-Cell Malignancies No dispute reported 06/30/2026 1190333063
Principal investigator 1 BeOne Medicines USA, Inc. $649.00 05/30/2025 Non-covered Recipient Entity
Comprehensive Cancer Centers of Nevada - Central Valley
A Phase 4, Observational Study Evaluating the Efficacy and Safety of the Bruton Tyrosine Kinase (BTK) Inhibitor Zanubrutinib in Patients With Waldenström Macroglobulinemia No dispute reported 06/30/2026 1190330913
Principal investigator 1 Sumitomo Pharma America, Inc. $1,943.00 05/29/2025 Non-covered Recipient Entity
COMPREHENSIVE CANCER CENTERS OF NEVEDA
A PHASE I, FIRST-IN-HUMAN, OPEN-LABEL, DOSE ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP 1454 No dispute reported 06/30/2026 1176635237
Principal investigator 1 Sumitomo Pharma America, Inc. $2,500.00 05/29/2025 Non-covered Recipient Entity
COMPREHENSIVE CANCER CENTERS OF NEVEDA
A PHASE I, FIRST-IN-HUMAN, OPEN-LABEL, DOSE ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP 1454 No dispute reported 06/30/2026 1176635244
Principal investigator 1 Sumitomo Pharma America, Inc. $4,500.00 05/29/2025 Non-covered Recipient Entity
COMPREHENSIVE CANCER CENTERS OF NEVEDA
A PHASE I, FIRST-IN-HUMAN, OPEN-LABEL, DOSE ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP 1454 No dispute reported 06/30/2026 1176635252
Principal investigator 1 Sumitomo Pharma America, Inc. $737.00 05/29/2025 Non-covered Recipient Entity
COMPREHENSIVE CANCER CENTERS OF NEVEDA
A PHASE I, FIRST-IN-HUMAN, OPEN-LABEL, DOSE ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP 1454 No dispute reported 06/30/2026 1176635256
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $108.17 05/27/2025 Non-covered Recipient Entity
Comprehensive Cancer Centers Of Nevada
A Phase 2 Randomized, Open Label Study to Evaluate the Efficacy and Safety of Golcadomide in Combination with Rituximab in Patients with Newly Diagnosed Advanced Stage Follicular Lymphoma No dispute reported 06/30/2026 1235997856
Principal investigator 1 PFIZER INC. $15,546.68 05/27/2025 Non-covered Recipient Entity
ALLISON CURTIS KINGSLEY ET AL
A PHASE 1 STUDY OF SGNB6A IN ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1228772643
Principal investigator 1 BeiGene, Ltd. $10,192.00 05/23/2025 Non-covered Recipient Entity
Comprehensive Cancer Centers of Nevada - Central Valley
An International, Phase 2, Open-Label, Randomized Study of BGB-3111 Combined With Obinutuzumab Compared With Obinutuzumab Monotherapy in Relapsed/ Refractory Follicular Lymphoma No dispute reported 06/30/2026 1190320874
Principal investigator 1 BeiGene, Ltd. $1,290.00 05/16/2025 Non-covered Recipient Entity
Comprehensive Cancer Centers of Nevada - Central Valley
An Open-label, Multi-center, Long-term Extension Study of Zanubrutinib (BGB-3111) Regimens in Patients With B-cell Malignancies No dispute reported 06/30/2026 1190325624
Principal investigator 1 BeiGene, Ltd. $1,667.00 04/29/2025 Non-covered Recipient Entity
Comprehensive Cancer Centers of Nevada - Central Valley
A Phase 1/2, Open-Label, Dose-Escalation and -Expansion Study of the Bruton Tyrosine Kinase Targeted Protein Degrader BGB-16673 in Patients With B-Cell Malignancies No dispute reported 06/30/2026 1190323274
Principal investigator 1 PFIZER INC. $23,590.88 04/29/2025 Non-covered Recipient Entity
Compr CA Centers of Nev
A PHASE 1 STUDY OF SGNB6A IN ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1228754617
Principal investigator 1 PFIZER INC. $23,590.88 04/28/2025 Non-covered Recipient Entity
Compr CA Centers of Nev
A PHASE 1 STUDY OF SGNB6A IN ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1228756068
Principal investigator 1 BeiGene, Ltd. $1,793.00 04/21/2025 Non-covered Recipient Entity
Comprehensive Cancer Centers of Nevada - Central Valley
A Phase 3 Randomized, Open-Label, Multicenter Study Comparing Zanubrutinib (BGB-3111) Plus Rituximab Versus Bendamustine Plus Rituximab in Patients With Previously Untreated Mantle Cell Lymphoma Who Are Ineligible for Stem Cell Transplantation No dispute reported 06/30/2026 1190325616
Principal investigator 1 BeOne Medicines USA, Inc. $7,081.00 04/17/2025 Non-covered Recipient Entity
Comprehensive Cancer Centers of Nevada - Central Valley
A Phase 4, Observational Study Evaluating the Efficacy and Safety of the Bruton Tyrosine Kinase (BTK) Inhibitor Zanubrutinib in Patients With Waldenström Macroglobulinemia No dispute reported 06/30/2026 1190330915
Principal investigator 1 PFIZER INC. $232.40 04/10/2025 Non-covered Recipient Entity
Compr CA Centers of Nev
A PHASE 1 STUDY OF SGNB6A IN ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1228755588
Principal investigator 1 PFIZER INC. $232.40 04/09/2025 Non-covered Recipient Entity
Compr CA Centers of Nev
A PHASE 1 STUDY OF SGNB6A IN ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1228754925
Principal investigator 1 BeiGene, Ltd. $5,270.00 04/08/2025 Non-covered Recipient Entity
Comprehensive Cancer Centers of Nevada - Central Valley
A Phase 1/2, Open-Label, Dose-Escalation and -Expansion Study of the Bruton Tyrosine Kinase Targeted Protein Degrader BGB-16673 in Patients With B-Cell Malignancies No dispute reported 06/30/2026 1190323276
Principal investigator 1 PFIZER INC. $232.40 03/28/2025 Non-covered Recipient Entity
Compr CA Centers of Nev
A PHASE 1 STUDY OF SGNB6A IN ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1228758061
Principal investigator 1 PFIZER INC. $232.40 03/27/2025 Non-covered Recipient Entity
Compr CA Centers of Nev
A PHASE 1 STUDY OF SGNB6A IN ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1228754872
Principal investigator 1 BeiGene, Ltd. $3,053.70 03/25/2025 Non-covered Recipient Entity
Comprehensive Cancer Centers of Nevada - Central Valley
An International, Phase 3, Open-Label, Randomized Study of BGB-3111 Compared With Bendamustine Plus Rituximab in Patients With Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (CLL/SLL) No dispute reported 06/30/2026 1190323280
Principal investigator 1 PFIZER INC. $10,518.32 03/24/2025 Non-covered Recipient Entity
ALLISON CURTIS KINGSLEY ET AL
A PHASE 1 STUDY OF SGNB6A IN ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1228787704
Principal investigator 1 PFIZER INC. $232.40 03/17/2025 Non-covered Recipient Entity
Compr CA Centers of Nev
A PHASE 1 STUDY OF SGNB6A IN ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1228755585
Principal investigator 1 PFIZER INC. $232.40 03/15/2025 Non-covered Recipient Entity
Compr CA Centers of Nev
A PHASE 1 STUDY OF SGNB6A IN ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1228756450
Principal investigator 1 Sumitomo Pharma America, Inc. $5,898.36 03/13/2025 Non-covered Recipient Entity
COMPREHENSIVE CANCER CENTERS OF NEVEDA
A PHASE I, FIRST-IN-HUMAN, OPEN-LABEL, DOSE ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP 1454 No dispute reported 06/30/2026 1176630532
Principal investigator 1 Sumitomo Pharma America, Inc. $4,488.34 03/13/2025 Non-covered Recipient Entity
COMPREHENSIVE CANCER CENTERS OF NEVEDA
A PHASE I, FIRST-IN-HUMAN, OPEN-LABEL, DOSE ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP 1454 No dispute reported 06/30/2026 1176630537
Principal investigator 1 PFIZER INC. $6,500.00 03/10/2025 Non-covered Recipient Entity
ALLISON CURTIS KINGSLEY ET AL
A PHASE 1 STUDY OF SGNB6A IN ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1228796169
Principal investigator 1 BeiGene, Ltd. $10,494.00 03/04/2025 Non-covered Recipient Entity
Comprehensive Cancer Centers of Nevada - Central Valley
A Phase 1/2, Open-Label, Dose-Escalation and -Expansion Study of the Bruton Tyrosine Kinase Targeted Protein Degrader BGB-16673 in Patients With B-Cell Malignancies No dispute reported 06/30/2026 1190323270
Principal investigator 1 Sumitomo Pharma America, Inc. $4,595.54 02/20/2025 Non-covered Recipient Entity
COMPREHENSIVE CANCER CENTERS OF NEVEDA
A PHASE I, FIRST-IN-HUMAN, OPEN-LABEL, DOSE ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP 1454 No dispute reported 06/30/2026 1176628352
Principal investigator 1 BeiGene, Ltd. $1,290.00 02/14/2025 Non-covered Recipient Entity
Comprehensive Cancer Centers of Nevada - Central Valley
An Open-label, Multi-center, Long-term Extension Study of Zanubrutinib (BGB-3111) Regimens in Patients With B-cell Malignancies No dispute reported 06/30/2026 1190319990
Principal investigator 1 PFIZER INC. $16,923.04 02/03/2025 Non-covered Recipient Entity
ALLISON CURTIS KINGSLEY ET AL
A PHASE 1 STUDY OF SGNB6A IN ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1228797408
Principal investigator 1 PFIZER INC. $200.00 02/03/2025 Non-covered Recipient Entity
ALLISON CURTIS KINGSLEY ET AL
A RANDOMIZED PHASE 3 OPENLABEL STUDY TO EVALUATE SGNB6A COMPARED WITH DOCETAXEL IN ADULT SUBJECTS WITH PREVIOUSLY TREATED NONSMALL CELL LUNG CANCER No dispute reported 06/30/2026 1228798110
Principal investigator 1 PFIZER INC. $116.20 01/31/2025 Non-covered Recipient Entity
Compr CA Centers of Nev
A PHASE 1 STUDY OF SGNB6A IN ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1228755922
Principal investigator 1 PFIZER INC. $116.20 01/30/2025 Non-covered Recipient Entity
Compr CA Centers of Nev
A PHASE 1 STUDY OF SGNB6A IN ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1228756072
Principal investigator 1 BeiGene, Ltd. $21,747.00 01/28/2025 Non-covered Recipient Entity
Comprehensive Cancer Centers of Nevada - Central Valley
A Phase 1/2, Open-Label, Dose-Escalation and -Expansion Study of the Bruton Tyrosine Kinase Targeted Protein Degrader BGB-16673 in Patients With B-Cell Malignancies No dispute reported 06/30/2026 1190323272
Recipient PFIZER INC. $330.00 01/27/2025 Covered Recipient Physician SIGVOTATUG VEDOTIN CLINICAL PUBLICATION PROGRAM No dispute reported 06/30/2026 1228770879
Principal investigator 1 BeiGene USA, Inc. $1,298.00 01/21/2025 Non-covered Recipient Entity
Comprehensive Cancer Centers of Nevada - Central Valley
A Phase 4, Observational Study Evaluating the Efficacy and Safety of the Bruton Tyrosine Kinase (BTK) Inhibitor Zanubrutinib in Patients With Waldenström Macroglobulinemia No dispute reported 06/30/2026 1190323278
Principal investigator 1 PFIZER INC. $1,600.00 01/21/2025 Non-covered Recipient Entity
ALLISON CURTIS KINGSLEY ET AL
A PHASE 1 STUDY OF SGNB6A IN ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1228798703
Principal investigator 1 BeiGene, Ltd. $10,075.00 01/17/2025 Non-covered Recipient Entity
Comprehensive Cancer Centers of Nevada - Central Valley
An International, Phase 2, Open-Label, Randomized Study of BGB-3111 Combined With Obinutuzumab Compared With Obinutuzumab Monotherapy in Relapsed/ Refractory Follicular Lymphoma No dispute reported 06/30/2026 1190325844
Principal investigator 1 Celgene Corporation $13,750.00 01/13/2025 Non-covered Recipient Entity
Comprehensive Cancer Centers Of Nevada
A Phase 2 Randomized, Open Label Study to Evaluate the Efficacy and Safety of Golcadomide in Combination with Rituximab in Patients with Newly Diagnosed Advanced Stage Follicular Lymphoma No dispute reported 06/30/2026 1222306463
Principal investigator 1 PFIZER INC. $23,590.88 01/08/2025 Non-covered Recipient Entity
Compr CA Centers of Nev
A PHASE 1 STUDY OF SGNB6A IN ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1228754851
Principal investigator 1 PFIZER INC. $47,181.76 01/08/2025 Non-covered Recipient Entity
Compr CA Centers of Nev
A PHASE 1 STUDY OF SGNB6A IN ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1228755241
Principal investigator 1 PFIZER INC. $232.40 01/08/2025 Non-covered Recipient Entity
Compr CA Centers of Nev
A PHASE 1 STUDY OF SGNB6A IN ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1228758057
Principal investigator 1 PFIZER INC. $23,590.88 01/07/2025 Non-covered Recipient Entity
Compr CA Centers of Nev
A PHASE 1 STUDY OF SGNB6A IN ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1228756378
Principal investigator 1 PFIZER INC. $232.40 01/07/2025 Non-covered Recipient Entity
Compr CA Centers of Nev
A PHASE 1 STUDY OF SGNB6A IN ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1228756382
Principal investigator 1 BeiGene, Ltd. $350.00 01/06/2025 Non-covered Recipient Entity
Comprehensive Cancer Centers of Nevada - Central Valley
A Phase 3 Randomized, Open-Label, Multicenter Study Comparing Zanubrutinib (BGB-3111) Plus Rituximab Versus Bendamustine Plus Rituximab in Patients With Previously Untreated Mantle Cell Lymphoma Who Are Ineligible for Stem Cell Transplantation No dispute reported 06/30/2026 1190320008
Principal investigator 1 BeiGene, Ltd. $750.00 01/06/2025 Non-covered Recipient Entity
Comprehensive Cancer Centers of Nevada - Central Valley
An Open-label, Multi-center, Long-term Extension Study of Zanubrutinib (BGB-3111) Regimens in Patients With B-cell Malignancies No dispute reported 06/30/2026 1190320070
Principal investigator 1 PFIZER INC. $47,181.76 01/06/2025 Non-covered Recipient Entity
Compr CA Centers of Nev
A PHASE 1 STUDY OF SGNB6A IN ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1228754825
Principal investigator 1 PFIZER INC. $5,200.00 01/06/2025 Non-covered Recipient Entity
ALLISON CURTIS KINGSLEY ET AL
A PHASE 1 STUDY OF SGNB6A IN ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1228798987